Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Up 36.9% in December

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) saw a significant increase in short interest in the month of December. As of December 15th, there was short interest totaling 13,528,238 shares, an increase of 36.9% from the November 30th total of 9,881,577 shares. Based on an average daily trading volume, of 24,227,526 shares, the days-to-cover ratio is currently 0.6 days. Currently, 17.0% of the company’s shares are sold short. Currently, 17.0% of the company’s shares are sold short. Based on an average daily trading volume, of 24,227,526 shares, the days-to-cover ratio is currently 0.6 days.

Aspire Biopharma Trading Up 31.5%

Aspire Biopharma stock opened at $0.14 on Wednesday. Aspire Biopharma has a 52 week low of $0.07 and a 52 week high of $15.80. The stock has a market cap of $15.26 million, a P/E ratio of -0.28 and a beta of 0.86. The stock has a 50 day moving average of $0.17 and a 200-day moving average of $0.31.

Aspire Biopharma (NASDAQ:ASBP) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.04) earnings per share (EPS) for the quarter. The company had revenue of $0.00 million during the quarter.

Institutional Trading of Aspire Biopharma

Several hedge funds have recently added to or reduced their stakes in the business. CIBC Bancorp USA Inc. bought a new position in shares of Aspire Biopharma in the third quarter worth $28,000. Jane Street Group LLC raised its stake in shares of Aspire Biopharma by 625.8% during the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock valued at $41,000 after purchasing an additional 131,533 shares in the last quarter. Optivise Advisory Services LLC lifted its holdings in Aspire Biopharma by 120.9% in the second quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock worth $63,000 after purchasing an additional 128,660 shares during the period. Crewe Advisors LLC boosted its stake in Aspire Biopharma by 100.0% during the 2nd quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock valued at $169,000 after purchasing an additional 313,427 shares in the last quarter. Finally, Procyon Advisors LLC raised its stake in shares of Aspire Biopharma by 558.3% in the 2nd quarter. Procyon Advisors LLC now owns 648,411 shares of the company’s stock worth $174,000 after buying an additional 549,911 shares in the last quarter. Institutional investors own 19.17% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aspire Biopharma in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.